Free Weekly Vaccines Industry Newsletter Get the latest news about Research Breakthroughs, R&D Trends, Clinical Trials, and Vaccine Production sent straight to your Inbox. Join over 25,000 lab research professionals who subscribe to FierceVaccines for FREE!

Sanofi teams up with VBI Vaccines to improve vaccine stability

Sanofi has been on a partnering roll lately and is continuing its streak with a new pact with VBI Vaccines.

VBI ($VBIV) announced Monday that it is collaborating with Sanofi's ($SNY) vaccines unit to apply its Lipid Particle Vaccine (LPV) to improve the stability of an undisclosed Sanofi Pasteur candidate. The terms of the agreement were not disclosed.

VBI's mission is to develop new technologies to help expand vaccine protection in large underserved markets. The unnamed vaccine is a "key" candidate in Sanofi Pasteur's pipeline and will be reformulated using the LPV technology, which could potentially confer thermostability up to 40ºC, according to a statement. This enables the production of vaccines and biologics that can withstand fluctuating temperatures during shipment, the company said.

"VBI is proud to be working with Sanofi Pasteur, a significant global vaccine manufacturer, to provide a more stable formulation of one of its key pipeline assets," said Jeff Baxter, president and CEO of Cambridge, MA-based VBI Vaccines, in a statement. "Our LPV technology has shown great promise in stabilizing vaccines and biologics of a variety of classes and targets. This collaboration reinforces the potential of our technology."

The collaboration is one of a series for Sanofi. In 2011, Sanofi Pasteur and Germany's CureVac teamed up to use the latter's RNActive technology to develop vaccines against several infectious diseases. Three years later, in 2014, they expanded their partnership with a deal that gave Sanofi rights to a new mRNA-based vaccine.

And in October 2014, Sanofi signed a deal with Immune Design in hopes to use the latter's GLAAS technology to galvanize the immune response from a herpes vaccine, after it tapped the GLAAS platform to develop new treatments for food allergies.

Comments

Join 25,000+ Insiders

SIGN UP FOR OUR NEWSLETTER

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join 25,000+ lab research professionals who get FierceVaccines via weekly email. Sign up today!

THE LIBRARY: WEBINAR

How to enable anywhere, any data access without compromising security

| Thursday, September 24th | 1pm ET / 10am PT | Sponsored by: M-Files

This webinar will discus how the emergence of the ability to share documents and data across thousands of miles instantly has pulled biopharma companies in two opposing directions. Companies want, even need, the interconnectivity that is facilitated by the Internet, but feel equally strongly about controlling who can view and interact with their data. Register today!

A publication ofFierceMarkets

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Click here to get your free weekly email briefing today!